Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Porus GmbH is a German veterinary biotechnology company specializing in the development of innovative, non-pharmaceutical solutions to support kidney health in companion animals, particularly cats. The company's flagship product, Porus One, is a veterinary supplement containing Renaltec, a patented selective carbon-based spherical adsorber that binds uremic toxin precursors (such as indole, phenol, and p-cresol) in the gut, preventing them from entering the bloodstream and burdening the kidneys. Porus also developed Catney One, a feed supplement designed to reduce phosphate absorption and support renal function in cats with chronic renal insufficiency. Distributed globally through partnerships with major animal health companies like Dechra and Virbac, Porus's products offer non-invasive, targeted options for managing feline chronic kidney disease.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Porus.